Retinalamin, lyophilizate 5 mg 22 mg 10 pcs

Retinalamin is a tissue repair stimulator. Retinalamin is a complex of water-soluble polypeptide fractions with a molecular weight of no more than 10,000 Da.

The drug has a stimulating effect on photoreceptors and cellular elements of the retina and improves functional interaction of the pigment epithelium and outer segments of the photoreceptors and glial cells in case of dystrophic changes and accelerates restoration of light sensitivity of the retina.

Normalizes vascular permeability, reduces manifestations of local inflammatory reactions and stimulates reparative processes in retinal diseases and injuries.

The mechanism of action of Retinalamin is determined by its metabolic activity: the drug improves metabolism of eye tissue and normalizes cell membrane function, improves intracellular protein synthesis, regulates lipid peroxidation and helps optimize energy processes.

Pharmacokinetics

The composition of Retinalamin, the active substance of which is a complex of polypeptide fractions, does not allow the usual pharmacokinetic analysis of its components.

Indications

Active ingredient

Composition

1 vial contains:

Active substance:

retinalamin (complex of water-soluble polypeptide fractions of the cattle retina) 5 mg;

Auxiliary substance:

Glycine 17 mg.

How to take, the dosage

Adults

In diabetic retinopathy, central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy – parabulbar or intravenous 5-10 mg once daily.

The course of treatment is 5-10 days; repeated in 3-6 months if necessary.

In compensated primary open angle glaucoma – parabulbar or intramural 5 mg once a day. The course of treatment is 10 days; if necessary it is repeated in 3-6 months.

In case of myopic disease – parabulbar 5 mg once a day. The course of treatment is 10 days. It is recommended in combination with angioprotective agents and B-group vitamins.

The drug is dissolved in 1-2 ml of water for injection, 0.9% sodium chloride solution or 0.5% procaine (novocaine) solution with the needle directed to the wall of the bottle to avoid foaming.

In children aged 1-5 years

In central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy – parabulbar or intravenous 2.5 mg once daily.

In children 6-18 years of age

In case of central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy – parabulbar or intravenous 2.5-5 mg once daily.

The drug is dissolved in 1-2 ml of 0.9% sodium chloride solution, directing the needle toward the wall of the bottle to avoid foaming. The course of treatment is 10 days; if necessary, it is repeated after 3-6 months.

Precautionary measures for use. Retinalamin® should be used only if prescribed by a doctor!

The bottle with the dissolved drug must not be stored or used after storage.

The solution of Retinalamin® should not be mixed with other solutions.

Contraindications

Pregnancy use

The drug is contraindicated in pregnancy (no data on efficacy and safety).

Breastfeeding should be stopped if the drug has to be prescribed during lactation.